



Paris, January 26th, 2012

## **STENTYS raises € 7.5 million in capital**

**PRINCETON, NJ and PARIS, Jan. 26, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing Stent to treat Acute Myocardial Infarction (AMI), announces today the completion of a capital increase without preferential subscription rights through an accelerated book-building (the "Private Placement"). STENTYS will use the net proceeds of the capital increase to pursue its clinical and commercial development in Europe and in the United States of America.**

**STENTYS has conducted the Private Placement of 518,776 shares, for an aggregate amount of € 7.5 million reserved to qualified investors in the European Economic Area and Switzerland, not including the United States of America, Canada, Australia and Japan and in accordance with Article L.411-2 II of the French Monetary and Financial Code.**

**The subscription price of the new shares has been set at €14.50 per share, resulting from the confrontation of supply and demand of shares from investors pursuant to a book-building process admitted as professional practice.**

**This subscription price shows a 14% discount to the volume weighted average price of the last 3 trading days preceding the pricing (i.e. 16.8694 euros) in accordance with the authorizations decided by the annual general meeting dated May 31, 2011.**

**The Private Placement has been managed by Société Générale Corporate & Investment Banking and Kempen & Co as Joint-Lead Managers and Joint-Bookrunners.**

**In connection with the Private Placement, the Company has entered into a lock-up agreement pursuant to which it has agreed not to issue or sell any ordinary STENTYS shares for a period ending 90 days after the settlement and the delivery of the Private Placement.**

**The new shares will be fully fungible with and listed on the regulated market of NYSE Euronext in Paris on the same line as the existing ordinary shares of the Company under ISIN code FR0010949404. The settlement-delivery of the new shares will take place on January 31<sup>st</sup>, 2012.**

**Gonzague Issenmann, Chief Executive Officer and Co-Founder of STENTYS said: "With this capital increase, a clear sign of confidence from investors in these still uncertain financial markets, STENTYS enjoys a solid cash base to continue the execution of its clinical and commercialization strategy and to make the Self-Apposing technology the new standard of care for heart attack patients"**

### **About STENTYS:**

Based in Paris (France) and Princeton, N.J. (USA), the STENTYS Company has developed a new generation of stents to treat acute myocardial infarction. Founded by Jacques Séguin, Professor of Cardiac Surgery, and Gonzague Issenmann, STENTYS received the CE mark for its flagship products in 2010. Its self-apposing stents adapt the anatomic changes of the arteries in the post-infarction phase and prevents conventional stents mal-apposition problems. STENTYS has started its marketing activities in several European countries.

*More information about the company on the website: [www.stentys.com](http://www.stentys.com)*

### **STENTYS**

Stanislas Piot  
CFO  
Tel.: +33 (0)1 44 53 99 42  
[investors@stentys.com](mailto:investors@stentys.com)

### **NewCap.**

Investor Relations  
Axelle Vuillermet / Pierre Laurent  
Tel. : +33 (0)1 44 71 94 94  
[stentys@newcap.fr](mailto:stentys@newcap.fr)

STENTYS is listed on NYSE Euronext Paris (Compartment C)  
ISIN: FR0010949404 – Ticker : STNT

Disclaimer

This announcement does not, and shall not, in any circumstances, constitute a public offering nor an offer to subscribe nor an invitation to the public in any jurisdiction in connection with any offer.

This press release does not constitute or form part of an offer or solicitation of an offer to subscribe for securities in France. The securities referred to herein may not be and will not be offered or sold to the public in France except to qualified investors, acting for their own account, as defined in, and in accordance with Articles L. 411-2 II and D. 411-1 to D. 411-3 of the French Monetary and Financial Code.

With respect to the member states of the European Economic Area which have implemented the Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003, as amended, in particular by Directive 2010/73/EC of the European Parliament and of the Council of November 24, 2010 (the "Prospectus Directive"), no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member state. As a result, the securities may not and will not be offered in any relevant member state except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member state, or under any other circumstances which do not require the publication by STENTYS of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member state.

This announcement and the information contained herein do not constitute an offer or solicitation of an offer to subscribe for securities in the United States or any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The shares of STENTYS have not been and will not be registered under the U.S. Securities Act and. STENTYS does not intend to register securities or conduct a public offering in the United States.

In the United Kingdom, this document is only being distributed to, and is only directed at, persons that are "qualified investors" within the meaning of Article 2(1)(e)(i), (ii) or (iii) of the Prospectus Directive and that also (i) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). In the United Kingdom, this document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.

The distribution of this announcement in certain countries may be subject to specific regulations. The persons in possession of this announcement shall then get knowledge of any local restrictions and shall comply with these restrictions.

Any decision to subscribe for shares STENTYS should only be made on the basis of public information about STENTYS. This information does not fall under the responsibility of Société Générale Corporate & Investment Banking and Kempen & Co and have not been independently verified by Société Générale Corporate & Investment Banking and Kempen & Co.

No copy of this announcement has been or should be distributed or sent to the United States, Canada, Japan or Australia.